127 related articles for article (PubMed ID: 26843342)
1. Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them?
Rogler G
Aliment Pharmacol Ther; 2016 Mar; 43(5):651-2. PubMed ID: 26843342
[No Abstract] [Full Text] [Related]
2. Editorial: how to interpret risks and prediction of complications in Crohn's disease--can our patients interpret them? Authors' reply.
Siegel CA; Dubinsky MC
Aliment Pharmacol Ther; 2016 Mar; 43(5):653. PubMed ID: 26843343
[No Abstract] [Full Text] [Related]
3. Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's disease.
Peyrin-Biroulet L; Colombel JF; Sandborn WJ
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1139. PubMed ID: 19465159
[No Abstract] [Full Text] [Related]
4. Editorial: preventing disease progression in Crohn's--can we shut the stable door before the horse bolts?
Hawthrone AB
Aliment Pharmacol Ther; 2015 Nov; 42(9):1131-2. PubMed ID: 26427754
[No Abstract] [Full Text] [Related]
5. A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables.
Siegel CA; Horton H; Siegel LS; Thompson KD; Mackenzie T; Stewart SK; Rice PW; Stempak JM; Dezfoli S; Haritunians T; Levy A; Baek M; Milgrom R; Dulai PS; Targan SR; Silverberg MS; Dubinsky MC; McGovern DP
Aliment Pharmacol Ther; 2016 Jan; 43(2):262-71. PubMed ID: 26567467
[TBL] [Abstract][Full Text] [Related]
6. [Biological compounds in the treatment of Crohn's disease].
Dinari G
Harefuah; 2001 Apr; 140(4):316-8. PubMed ID: 11303396
[No Abstract] [Full Text] [Related]
7. Review article: loss of response to anti-TNF treatments in Crohn's disease.
Ben-Horin S; Chowers Y
Aliment Pharmacol Ther; 2011 May; 33(9):987-95. PubMed ID: 21366636
[TBL] [Abstract][Full Text] [Related]
8. Biologics in pediatric Crohn's disease: is it time to move to an earlier therapeutic approach?
Hyams JS
Expert Rev Clin Immunol; 2014 Nov; 10(11):1423-6. PubMed ID: 25340425
[TBL] [Abstract][Full Text] [Related]
9. [Esophageal Crohn's disease].
Gil-Simón P; Barrio J; Saracíbar E; Pérez-Miranda M; Julián L; Antonio Gil Ruiz J; Caro-Patón A
Gastroenterol Hepatol; 2008 Feb; 31(2):108-9. PubMed ID: 18279653
[No Abstract] [Full Text] [Related]
10. Adjunctive treatment to antitumor necrosis factor in pediatric patients with refractory Crohn's disease.
Absah I; Stephens M
Curr Opin Pediatr; 2013 Oct; 25(5):624-8. PubMed ID: 23995433
[TBL] [Abstract][Full Text] [Related]
11. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
12. Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
Yadav A; Foromera J; Falchuk KR; Feuerstein JD
Scand J Gastroenterol; 2018; 53(7):813-817. PubMed ID: 29719998
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of abdominal ultrasonography in the analysis of endoscopic activity in patients with Crohn's disease: changes following treatment with immunomodulators and/or anti-TNF antibodies.
Moreno N; Ripollés T; Paredes JM; Ortiz I; Martínez MJ; López A; Delgado F; Moreno-Osset E
J Crohns Colitis; 2014 Sep; 8(9):1079-87. PubMed ID: 24613399
[TBL] [Abstract][Full Text] [Related]
14. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA
Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
[No Abstract] [Full Text] [Related]
15. Update on the Medical Management of Crohn's Disease.
Deepak P; Bruining DH
Curr Gastroenterol Rep; 2015 Nov; 17(11):41. PubMed ID: 26363802
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery.
Herfarth HH
Clin Gastroenterol Hepatol; 2014 Sep; 12(9):1503-6. PubMed ID: 24534549
[No Abstract] [Full Text] [Related]
17. Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn's disease with poor prognostic factors.
Oh EH; Oh K; Han M; Seo H; Chang K; Lee SH; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
PLoS One; 2017; 12(5):e0177479. PubMed ID: 28542298
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Hanauer SB
Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
[TBL] [Abstract][Full Text] [Related]
19. Oral tuberculosis in a patient with Crohn's disease on TNF-α blockers.
Reynaert V; Grosber M; Tache A; Mana F; Buydens P; Lacor P; Gutermuth J
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):e236-e237. PubMed ID: 32977350
[No Abstract] [Full Text] [Related]
20. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
Shivashankar R; Pardi DS
Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
